AR022649A1 - Procedimiento para la obtencion de inhibidores de 5-lipooxigenasa con distintos sistemas de anillos heterociclos. - Google Patents

Procedimiento para la obtencion de inhibidores de 5-lipooxigenasa con distintos sistemas de anillos heterociclos.

Info

Publication number
AR022649A1
AR022649A1 ARP000104488A ARP000104488A AR022649A1 AR 022649 A1 AR022649 A1 AR 022649A1 AR P000104488 A ARP000104488 A AR P000104488A AR P000104488 A ARP000104488 A AR P000104488A AR 022649 A1 AR022649 A1 AR 022649A1
Authority
AR
Argentina
Prior art keywords
formula
group
salt
reaction mixture
heterocicles
Prior art date
Application number
ARP000104488A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR022649A1 publication Critical patent/AR022649A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un procedimiento de preparacion de compuestos de formula (1) en la que (2) es el grupo (3) que comprende: el establecimiento de una mezcla de reaccionconstituida por (4) y el grupo (5) en un disolvente aproticoen presencia de una base fuerte en formasolida seleccionada entre el grupn constituido porhidroxido de sodio NaOH, e hidroxido de potasio KOH, y opcionalmente, en presencia de una cantidad catalítica de carbonato de cesio Cs2CO3, o un catalizadorde transferencia de fase, especialmente unasal de amonio cuaternaria o sal de fosfonio, seguido del calentamiento de la citada mezcla de reaccion en atmosferade nitrogeno, produciéndose un compuesto de formula (1), y en una realizacion preferida, el disolvente aprotico es DMSO, la base fuerte en forma solida esNaOH en polvo o en gránulos, y el catalizador de transferencia de fase es cloruro de tetra-n-butilamonio (TBAC), que se utiliza para preparar un compuestopreferido, util como inhibidor de 5-lipooxigenasa, de formula (6) y especialmente la sal metanosulfonato sustancialmente pura de éste.
ARP000104488A 1999-08-31 2000-08-29 Procedimiento para la obtencion de inhibidores de 5-lipooxigenasa con distintos sistemas de anillos heterociclos. AR022649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161199P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
AR022649A1 true AR022649A1 (es) 2002-09-04

Family

ID=22539515

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104488A AR022649A1 (es) 1999-08-31 2000-08-29 Procedimiento para la obtencion de inhibidores de 5-lipooxigenasa con distintos sistemas de anillos heterociclos.

Country Status (19)

Country Link
US (1) US6344563B1 (es)
EP (1) EP1081146A1 (es)
JP (1) JP2001106687A (es)
KR (1) KR20010050224A (es)
CN (1) CN1291609A (es)
AR (1) AR022649A1 (es)
AU (1) AU5360700A (es)
BR (1) BR0003875A (es)
CA (1) CA2317001A1 (es)
CZ (1) CZ20003160A3 (es)
HU (1) HUP0003438A3 (es)
ID (1) ID29315A (es)
IL (1) IL138088A0 (es)
MX (1) MXPA00008505A (es)
PL (1) PL342284A1 (es)
RU (1) RU2177005C1 (es)
TR (1) TR200002523A2 (es)
YU (1) YU52800A (es)
ZA (1) ZA200004436B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009279A (es) 2000-03-24 2004-09-10 Euro Celtique Sa Pirazoles, triazoles y tetrazoles sustituidos con arilo como bloqueadores del canal de sodio.
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753682A (en) * 1993-06-14 1998-05-19 Pfizer Inc. Imidazole lipoxygenase inhibitors
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
PT863905E (pt) * 1995-09-18 2001-03-30 Pfizer Novos inibidores da lipoxigenase do imidazolo

Also Published As

Publication number Publication date
HUP0003438A3 (en) 2002-08-28
CA2317001A1 (en) 2001-02-28
YU52800A (sh) 2003-08-29
TR200002523A2 (tr) 2001-04-20
MXPA00008505A (es) 2005-07-25
IL138088A0 (en) 2001-10-31
PL342284A1 (en) 2001-03-12
AU5360700A (en) 2001-03-08
EP1081146A1 (en) 2001-03-07
CZ20003160A3 (cs) 2001-10-17
ZA200004436B (en) 2002-02-28
CN1291609A (zh) 2001-04-18
JP2001106687A (ja) 2001-04-17
ID29315A (id) 2001-08-16
US6344563B1 (en) 2002-02-05
RU2177005C1 (ru) 2001-12-20
BR0003875A (pt) 2001-12-11
HU0003438D0 (en) 2000-08-30
HUP0003438A2 (hu) 2001-08-28
KR20010050224A (ko) 2001-06-15

Similar Documents

Publication Publication Date Title
Li et al. General and efficient method for direct N-monomethylation of aromatic primary amines with methanol
Chen et al. Intramolecular Aryl Migration of Diaryliodonium Salts: Access to ortho‐Iodo Diaryl Ethers
CO6170362A2 (es) Procedimiento de preparacion de halogenuros de n-alquil-naltrexona
CR7691A (es) Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
ES2431163T3 (es) Inhibidores de PIM quinasa y métodos para su uso
AR022649A1 (es) Procedimiento para la obtencion de inhibidores de 5-lipooxigenasa con distintos sistemas de anillos heterociclos.
AR058187A1 (es) Sintesis de un intermediario y formas polimorficas del mismo que se utilizan para la preparacion de clorhidrato de donepezilo.
AR076969A1 (es) Un procedimiento para la preparacion de febuxostat
AR047686A1 (es) Un procedimiento de sintesis de compuestos de 1,3-dihidro-2h-3-benzazepin-2-ona, y su aplicacion a la sintesis de la ivabradina y sus sales de adicion con un acido farmaceuticamente aceptable
ES8107138A1 (es) Procedimiento para preparar o-metaliloxifenol.
JPWO2007145278A1 (ja) グリシドールの製造方法
CO5650178A2 (es) Metal de niquel y procedmiento para producir el mismo
AR029767A1 (es) Procedimiento para la preparacion de compuestos de pirazolo (4, 3-d) pirimidin-7-onas-3-piridilsulfonilo y compuestos intermediarios utiles en dicho procedimiento.
ES414365A1 (es) Procedimiento para la preparacion de nuevos derivados del acido p-dihidroxibencenodisulfonico.
UA98492C2 (ru) Способ получения бромопикрина
CR9424A (es) Ibuprofeno solubilizado
JPS55122779A (en) Preparation of theobromine derivative
PA8499601A1 (es) Procedimientos para preparar inhibidores de 5-lipoxigenasa que tienen sistemas anuladores heterociclicos variados
JPS537640A (en) Synthesis of diphenylamine derivatives
TW200708635A (en) Mediator systems for electrochemical reduction of organic compounds in aqueous solution
KR20170030193A (ko) 스티레네이티드 페놀 유도체의 제조방법
BR0302681B1 (pt) Método para a produção de um composto de éter
TH70892A (th) กรรมวิธีสำหรับการเตรียมอะริไพพราโชล
AR117436A1 (es) Proceso para preparar compuestos farmacéuticos e intermedios
AR012307A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE SALES DEL ÁCIDO CLAVULÁNICO.

Legal Events

Date Code Title Description
FB Suspension of granting procedure